Non Hodgkin Lymphoma Clinical Trial

Clinical Trial Finder Non Hodgkin Lymphoma Trials

Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin’s Lymphoma (B-NHL)

See Locations Near You

Summary

The purpose of this study is to assess the safety and efficacy of IMM0306-02 in patients with refractory or relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

18-75 years old
Diagnosed with B-NHL
Relapsed after or be refractory to at least 2 line of standard therapy

Exclusion Criteria:

Active central nervous system (CNS) metastases
Positive Direct Antiglobulin Test (DAT)
Active autoimmune disorder
Skin disorders that do not requires hormone replacement therapy

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

90

Study ID:

NCT04746131

Recruitment Status:

Suspended

Sponsor:

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

The Christ Hospital
Cincinnati Ohio, 45219, United States

How clear is this clinincal trial information?

Study is for people with:

Non Hodgkin Lymphoma

Phase:

Phase 1

Estimated Enrollment:

90

Study ID:

NCT04746131

Recruitment Status:

Suspended

Sponsor:


ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
Clinical Trials Can be Life-Saving for Some
Clinical Trials Test State-of-the-Art Cancer Treatments
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider